You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Obtenez les dernières mises à jour ou faites une autoévaluation.

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Lignes directrices et conseils
À propos des lignes directrices

Screening for Secondary Solid Malignancies after Stem Cell Transplant

Version: 2 mar 2022
Type of Content: Guidelines & Advice, Position Statement
Document Status: Current
Authors:
Stem Cell Transplant Survivorship Community of Practice, Stem Cell Transplant Advisory Committee

Guideline Objective

To inform primary care providers in the screening of secondary solid malignancies in patients following an autologous or allogeneic stem cell transplant.

Patient Population

Patients undergoing an autologous or allogeneic stem cell transplant.

Intended Guideline Users

Primary care for patients undergoing autologous or allogeneic stem cell transplantation.

pdf download Full Report (PDF) (164.47 Ko)